Neurocrine Biosciences, Inc. (NBIX)

78.43
NASDAQ
Prev Close 78.43
Day Low/High 0.00 / 0.00
52 Wk Low/High 64.72 / 126.98
Exchange NASDAQ
Shares Outstanding 90.82B
Market Cap 7.12B
Div & Yield N.A. (N.A)

Latest News

Neurocrine Biosciences To Present At Upcoming Healthcare Conferences

Neurocrine Biosciences To Present At Upcoming Healthcare Conferences

SAN DIEGO, March 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the following investor...

Neurocrine Biosciences Reports Fourth Quarter And Year-End 2018 Financial Results

Neurocrine Biosciences Reports Fourth Quarter And Year-End 2018 Financial Results

INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $130.3 Million with Approximately 22,900 TRx

New INGREZZA® (valbenazine) Analysis Published In The Journal Of Affective Disorders Demonstrates Sustained Improvement In Tardive Dyskinesia Symptoms In Patients With Primary Mood Disorders

New INGREZZA® (valbenazine) Analysis Published In The Journal Of Affective Disorders Demonstrates Sustained Improvement In Tardive Dyskinesia Symptoms In Patients With Primary Mood Disorders

INGREZZA Significantly Reduced the Symptoms of Involuntary Movements in Patients with Bipolar or Major Depressive Disorder in Post-Hoc Analysis

Neurocrine Biosciences Announces Conference Call And Webcast Of Fourth Quarter And Year-End 2018 Financial Results

Neurocrine Biosciences Announces Conference Call And Webcast Of Fourth Quarter And Year-End 2018 Financial Results

Conference Call and Webcast Scheduled for Tuesday, February 5

Neurocrine Biosciences Provides Preliminary Fourth Quarter And Full-Year 2018 Net Product Sales Results And 2019 Program Milestones

Neurocrine Biosciences Provides Preliminary Fourth Quarter And Full-Year 2018 Net Product Sales Results And 2019 Program Milestones

- INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $130 Million with Approximately 22,900 TRx

Neurocrine Biosciences To Present At The 37th Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences To Present At The 37th Annual J.P. Morgan Healthcare Conference

Live Audio Webcast will be on January 7, 2019

AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding In Women With Uterine Fibroids At 2018 AAGL Global Congress

AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding In Women With Uterine Fibroids At 2018 AAGL Global Congress

-Elagolix, in combination with add-back therapy, achieved statistically significant reduction in heavy menstrual bleeding associated with uterine fibroids compared to placebo

Neurocrine Biosciences To Present At The Jefferies 2018 London Healthcare Conference

Neurocrine Biosciences To Present At The Jefferies 2018 London Healthcare Conference

Live Audio Webcast will be on November 14, 2018

Neurocrine Biosciences Reports Third Quarter 2018 Financial Results

Neurocrine Biosciences Reports Third Quarter 2018 Financial Results

INGREZZA® (valbenazine) Third Quarter Net Product Sales of $111.3 Million with Approximately 19,400 TRx

Neurocrine Biosciences To Present New Data Analyses On The Long-Term Effects Of INGREZZA® (valbenazine) In Tardive Dyskinesia Patients With Mood Disorders At The 2018 Annual Psych Congress

Neurocrine Biosciences To Present New Data Analyses On The Long-Term Effects Of INGREZZA® (valbenazine) In Tardive Dyskinesia Patients With Mood Disorders At The 2018 Annual Psych Congress

New Data Also Examine the Impact of Uncontrollable Movements as Reported by Patients, Caregivers and Healthcare Providers from RE-KINECT, the Largest Real-World Screening Study of Patients with Possible Tardive Dyskinesia

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AJRD, BXP, CARB, CDR, DOC, FTAI, GHDX, GOV, HOME, IKNX, LOCO, NBIX, NYLD.A, RFP, UEIC Downgrades: APU, HY, MFNC, SGMS, TFX Initiations: EEX, SSTI Read on to get TheStreet Quant Ratings' detailed report:

3 'Strong Buy' Healthcare Stocks Poised to Surge

3 'Strong Buy' Healthcare Stocks Poised to Surge

Here are the top healthcare bets ticking all the boxes for analysts.

5 Stocks That Are Screaming Buys Right Now

5 Stocks That Are Screaming Buys Right Now

Stay active and selective: These are the five best stocks to invest in right now

Spring Cleaning: Let's Tidy Up Some Trades

Spring Cleaning: Let's Tidy Up Some Trades

Not every trade can be a winner, so let's lighten the load here.

A Bullish Play on Neurocrine Biosciences

A Bullish Play on Neurocrine Biosciences

Analysts weren't shy to defend the company after Tuesday's earnings.

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

A roundup of biotech names with actions pending at the FDA in coming weeks.

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

Short Interest In Neurocrine Biosciences Increases 16%

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 1,118,638 share increase in total short interest for Neurocrine Biosciences, Inc. , to 8,122,994, an increase of 15.97% since 05/31/2017.

Biotech Movers: Inovio, Neurocrine, Alnylam

Biotech Movers: Inovio, Neurocrine, Alnylam

Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

Geopolitical concerns dominated market moves as banks kicked off earnings season.

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

Stocks closed lower Wednesday as markets continue to grapple with geopolitical uncertainty.

Wall Street Closes Lower Amid Continued Global Worries

Wall Street Closes Lower Amid Continued Global Worries

Stocks closed lower Wednesday as markets continue to grapple with geopolitical uncertainty.

TheStreet Quant Rating: C (Hold)